Pune: Infantry soldier Tariq Aziz (30) is set to return to active duty after undergoing a bilateral lung transplant — the ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

Liquidia stock shot higher Tuesday after its new drug, Yutrepia, widely beat prescription and patient start expectations.

The diagnosis of chronic obstructive pulmonary disease, or COPD, is improved by incorporating CT lung imaging and respiratory ...

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

Large cohort study finds interstitial lung disease independently increases lung cancer risk across all major subtypes, even ...

YUTREPIA surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerabil ...

The FDA has granted accelerated approval to Hernexeos for the treatment of adults with unresectable or metastatic non-squamous NSCLC.